DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] (NCT03529110)
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
🩺 Plain-English Summary (8th-Grade Level)
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
Who can join: Review the eligibility criteria below.
Location: UCLA Hematology Oncology — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (164 Sites)
Showing the first 25 of 164 sites.
- UCLA Hematology Oncology — Los Angeles, California
- Sharp Memorial Hospital — San Diego, California
- University of California San Francisco — San Francisco, California
- Innovative Clinical Research Institute — Whittier, California
- Washington Cancer Institute — Washington D.C., District of Columbia
- Florida Cancer Specialists-Broadway — Fort Myers, Florida
- Florida Cancer Specialists NORTH — St. Petersburg, Florida
- Piedmont Cancer Institute, PC — Atlanta, Georgia
- Loyola University Health System — Maywood, Illinois
- Norton Cancer Institute — Louisville, Kentucky
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Nebraska Medical Center — Omaha, Nebraska
- North Shore Hematology Oncology Associates, PC — East Setauket, New York
- University of Rochester — Rochester, New York
- Wake Forest University Baptist Medical Center — Winston-Salem, North Carolina
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Seidman Cancer Center — Cleveland, Ohio
- The Ohio State University — Columbus, Ohio
- Dayton Physicians, LLC — Kettering, Ohio
- Magee-Womens Hospital of UPMC — Pittsburgh, Pennsylvania
- Tennessee Oncology- St Thomas Location — Nashville, Tennessee
- Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
- UT Southwestern Medical Center — Dallas, Texas
- Houston Methodist Hospital / Houston Methodist Cancer Center — Houston, Texas
- MD Anderson Cancer Center — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.